Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6149800 | 0.88 | TPSAB1 (0.45) | ALDH1A1TPSAB1TPSD1TPSG1HTT | |
| SCHEMBL6152753 | 0.87 | TPSAB1 (0.43) | ALDH1A1TPSAB1TPSD1TPSG1GAA | |
| Hydrochloric Acid SCHEMBL6152281 | 0.86 | TPSAB1 (0.48) | TPSAB1TPSD1TPSG1GNAI3GNAO1 | |
| SCHEMBL6150351 | 0.85 | TPSAB1 (0.45) | ALDH1A1TPSAB1TPSD1TPSG1HTT | |
| SCHEMBL31282160 | 0.81 | GNAO1 (0.60) | TPSAB1TPSD1TPSG1GAAPOLB | |
| SCHEMBL6156540 | 0.79 | GPR119 (0.53) | GAAKDM4EPKM | |
| SCHEMBL314929 | 0.79 | CHRM4 (0.61) | ALDH1A1GAASMN1; SMN2MAPTKDM4E | |
| SCHEMBL6403134 | 0.78 | TPSAB1 (0.36) | ALDH1A1TPSAB1TPSD1TPSG1HTT | |
| SCHEMBL6403138 | 0.78 | TPSAB1 (0.36) | ALDH1A1TPSAB1TPSD1TPSG1HTT | |
| Hydrochloric Acid SCHEMBL6150359 | 0.78 | CHRM4 (0.60) | ALDH1A1GAASMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560589-A1 | NOVEL COMPLEXES OF FATTY ACID ESTERS OF POLYHYDROXYALKANES AND PYRIDINE CARBOXY DERIVATIVES | Astion Dermatology A/S (DK) | 2005-08-10 | — | — | EP | disclosed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004000333-A1 | NOVEL COMPLEXES OF FATTY ACID ESTERS OF POLYHYDROXYALKANES AND PYRIDINE CARBOXY DERIVATIVES | ASTION DERMATOLOGY A/S (DK) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | ALDH1A1 403/4885TPSAB1 113/4885TPSD1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.